1. Miller JJ, Kanack AJ, Dahms NM (2020) Progress in the understanding and treatment of Fabry disease. Biochim Biophys Acta Gen Subj 1864 1:129437. https://doi.org/10.1016/j.bbagen.2019.129437
2. Desnick RJ, Ioannou YA, Eng CM (2001) α-galactosidase A deficiency: Fabry disease. In: Scriver C, Beaudet A, Sly W et al (eds) The online metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York
3. Laney DA, Fernhoff PM (2008) Diagnosis of Fabry disease via analysis of family history. J Genet Couns 17(1):79–83. https://doi.org/10.1007/s10897-007-9128-x
4. Genzyme (2003) Fabrazyme (agalsidase beta). https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/agalgen042403LB.pdf. Accessed 21 Dec 2020
5. AB SHGT Replagal (agalsidase alpha). https://www.ema.europa.eu/en/documents/product-information/replagal-epar-product-information_en.pdf. Accessed 21 Dec 2020